Department of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada.
J Clin Rheumatol. 2011 Jun;17(4):204-6. doi: 10.1097/RHU.0b013e31821c0cae.
Allopurinol has been a standard hypouricemic agent for more than 40 years, but febuxostat, which is also a xanthine oxidase inhibitor, is now available. We present a case of tophaceous gout with uric acid levels that did not respond to prescription of very high doses of allopurinol or uricosuric agents. With febuxostat treatment, the patient had rapid and sustained reduction in her uric acid levels to target range. This case raises the possibility of currently unrecognized pharmacologic differences between allopurinol and febuxostat.
别嘌醇作为降尿酸药物已有 40 多年的历史，而黄嘌呤氧化酶抑制剂非布司他也已上市。我们报告了一例痛风石性痛风，尽管给予了极高剂量的别嘌醇或促尿酸排泄剂治疗，但患者的尿酸水平仍未得到控制。使用非布司他治疗后，患者的尿酸水平迅速且持续降至目标范围。该病例提示别嘌醇和非布司他之间可能存在目前尚未认识到的药理学差异。
